FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770293018> ?p ?o ?g. }

• W2770293018 endingPage "285" @default.
• W2770293018 startingPage "277" @default.
• W2770293018 abstract "Ruxolitinib and azacytidine target distinct disease manifestations of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPNs). Patients with MDS/MPNs initially received ruxolitinib BID (doses based on platelets count), continuously in 28-day cycles for the first 3 cycles. Azacytidine 25 mg/m2 (Day 1-5) intravenously or subcutaneously was recommended to be added to each cycle starting cycle 4 and could be increased to 75 mg/m2 (Days 1-5) for disease control. Azacytidine could be started earlier than cycle 4 and/or at higher dose in patients with rapidly proliferative disease or with elevated blasts. Thirty-five patients were treated (MDS/MPN-U, n =14; CMML, n =17; aCML, n =4), with a median follow-up of 15.2 months (range, 1.0-41.5). All patients were evaluable by the 2015 international consortium proposal of response criteria for MDS/MPNs (ICP MDS/MPN) and 20 (57%) responded. Nine patients (45%) responded after the addition of azacytidine. A greater than 50% reduction in palpable splenomegaly at 24 weeks was noted in 9/14 (64%) patients. Responders more frequently were JAK2-mutated (P = .02) and had splenomegaly (P = .03) compared to nonresponders. New onset grade 3/4 anemia and thrombocytopenia occurred in 18 (51%) and 19 (54%) patients, respectively, but required therapy discontinuation in only 1 (3%) patient. Patients with MDS/MPN-U had better median survival compared to CMML and aCML (26.5 vs 15.1 vs 8 months; P = .034). The combination of ruxolitinib and azacytidine was well-tolerated with an ICP MDS/MPN-response rate of 57% in patients with MDS/MPNs. The survival benefit was most prominent in patients with MDS/MPN-U." @default.
• W2770293018 created "2017-12-04" @default.
• W2770293018 creator A5002930476 @default.
• W2770293018 creator A5008503600 @default.
• W2770293018 creator A5010663972 @default.
• W2770293018 creator A5010786159 @default.
• W2770293018 creator A5013173470 @default.
• W2770293018 creator A5015140142 @default.
• W2770293018 creator A5018403822 @default.
• W2770293018 creator A5020340537 @default.
• W2770293018 creator A5046135731 @default.
• W2770293018 creator A5049385583 @default.
• W2770293018 creator A5055045706 @default.
• W2770293018 creator A5061026876 @default.
• W2770293018 creator A5064535224 @default.
• W2770293018 creator A5069121634 @default.
• W2770293018 creator A5069285537 @default.
• W2770293018 creator A5071687115 @default.
• W2770293018 creator A5073079562 @default.
• W2770293018 creator A5074515976 @default.
• W2770293018 creator A5084290698 @default.
• W2770293018 creator A5085521139 @default.
• W2770293018 creator A5088307376 @default.
• W2770293018 creator A5090435894 @default.
• W2770293018 date "2017-11-27" @default.
• W2770293018 modified "2023-10-18" @default.
• W2770293018 title "A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms" @default.
• W2770293018 cites W1503482160 @default.
• W2770293018 cites W1965033113 @default.
• W2770293018 cites W1974293265 @default.
• W2770293018 cites W1979622741 @default.
• W2770293018 cites W1986442976 @default.
• W2770293018 cites W1989167457 @default.
• W2770293018 cites W2007580297 @default.
• W2770293018 cites W2013425721 @default.
• W2770293018 cites W2029529782 @default.
• W2770293018 cites W2031657565 @default.
• W2770293018 cites W2035317270 @default.
• W2770293018 cites W2038795176 @default.
• W2770293018 cites W2039474819 @default.
• W2770293018 cites W2045496640 @default.
• W2770293018 cites W2047323080 @default.
• W2770293018 cites W2049630796 @default.
• W2770293018 cites W2052451894 @default.
• W2770293018 cites W2052836868 @default.
• W2770293018 cites W2053968609 @default.
• W2770293018 cites W2058219901 @default.
• W2770293018 cites W2061071302 @default.
• W2770293018 cites W2064240862 @default.
• W2770293018 cites W2066210952 @default.
• W2770293018 cites W2075614812 @default.
• W2770293018 cites W2078786399 @default.
• W2770293018 cites W2086355639 @default.
• W2770293018 cites W2092335024 @default.
• W2770293018 cites W2106584820 @default.
• W2770293018 cites W2107398329 @default.
• W2770293018 cites W2115038391 @default.
• W2770293018 cites W2115351357 @default.
• W2770293018 cites W2118771330 @default.
• W2770293018 cites W2121743767 @default.
• W2770293018 cites W2123633897 @default.
• W2770293018 cites W2126532431 @default.
• W2770293018 cites W2127559749 @default.
• W2770293018 cites W2132469484 @default.
• W2770293018 cites W2133283496 @default.
• W2770293018 cites W2138058759 @default.
• W2770293018 cites W2149089431 @default.
• W2770293018 cites W2155046477 @default.
• W2770293018 cites W2161021913 @default.
• W2770293018 cites W2179401874 @default.
• W2770293018 cites W2195128871 @default.
• W2770293018 cites W2267858353 @default.
• W2770293018 cites W2326726820 @default.
• W2770293018 cites W2339658711 @default.
• W2770293018 cites W2396508507 @default.
• W2770293018 cites W2405712018 @default.
• W2770293018 cites W2499002775 @default.
• W2770293018 cites W2559313212 @default.
• W2770293018 cites W2559562829 @default.
• W2770293018 cites W2617432132 @default.
• W2770293018 cites W2625242761 @default.
• W2770293018 cites W4242351610 @default.
• W2770293018 doi "https://doi.org/10.1002/ajh.24972" @default.
• W2770293018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29134664" @default.
• W2770293018 hasPublicationYear "2017" @default.
• W2770293018 type Work @default.
• W2770293018 sameAs 2770293018 @default.
• W2770293018 citedByCount "46" @default.
• W2770293018 countsByYear W27702930182018 @default.
• W2770293018 countsByYear W27702930182019 @default.
• W2770293018 countsByYear W27702930182020 @default.
• W2770293018 countsByYear W27702930182021 @default.
• W2770293018 countsByYear W27702930182022 @default.
• W2770293018 countsByYear W27702930182023 @default.
• W2770293018 crossrefType "journal-article" @default.
• W2770293018 hasAuthorship W2770293018A5002930476 @default.
• W2770293018 hasAuthorship W2770293018A5008503600 @default.
• W2770293018 hasAuthorship W2770293018A5010663972 @default.

• next